OneAscent Financial Services LLC Has $536,000 Holdings in Medtronic plc (NYSE:MDT)


Share on StockTwits

OneAscent Financial Services LLC increased its stake in shares of Medtronic plc (NYSE:MDT) by 9.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,576 shares of the medical technology company’s stock after buying an additional 382 shares during the quarter. OneAscent Financial Services LLC’s holdings in Medtronic were worth $536,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Spectrum Management Group LLC raised its position in shares of Medtronic by 317.5% during the third quarter. Spectrum Management Group LLC now owns 263 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 200 shares during the last quarter. Coastal Capital Group Inc. grew its stake in shares of Medtronic by 137.0% during the third quarter. Coastal Capital Group Inc. now owns 282 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 163 shares during the period. Crewe Advisors LLC acquired a new position in Medtronic in the third quarter valued at about $31,000. Catalyst Private Wealth LLC acquired a new position in Medtronic in the third quarter valued at about $31,000. Finally, Knuff & Co LLC grew its stake in Medtronic by 215.0% in the third quarter. Knuff & Co LLC now owns 315 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 215 shares during the period. Institutional investors and hedge funds own 68.87% of the company’s stock.

In related news, EVP Robert John White sold 10,930 shares of the stock in a transaction on Friday, December 18th. The shares were sold at an average price of $115.46, for a total transaction of $1,261,977.80. Following the sale, the executive vice president now directly owns 55,852 shares of the company’s stock, valued at $6,448,671.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Carol A. Surface sold 15,000 shares of the company’s stock in a transaction on Monday, December 28th. The stock was sold at an average price of $114.90, for a total transaction of $1,723,500.00. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by insiders.

MDT has been the topic of several analyst reports. Morgan Stanley upgraded Medtronic from an “equal weight” rating to an “overweight” rating and set a $140.00 target price on the stock in a report on Tuesday, December 15th. Piper Sandler upped their price objective on Medtronic from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, November 24th. BTIG Research upped their target price on Medtronic from $119.00 to $124.00 and gave the company a “buy” rating in a research report on Wednesday, November 25th. Sanford C. Bernstein raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 8th. Finally, Credit Suisse Group increased their price target on Medtronic from $118.00 to $126.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 25th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $120.93.

Shares of MDT stock opened at $118.72 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.16 and a quick ratio of 1.79. The company has a market capitalization of $159.80 billion, a price-to-earnings ratio of 45.31, a PEG ratio of 3.58 and a beta of 0.69. The company’s fifty day moving average price is $115.11 and its 200-day moving average price is $105.81. Medtronic plc has a one year low of $72.13 and a one year high of $122.15.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Monday, November 23rd. The medical technology company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.22. Medtronic had a net margin of 12.69% and a return on equity of 9.71%. The firm had revenue of $7.65 billion during the quarter, compared to analysts’ expectations of $7.05 billion. During the same period in the previous year, the company earned $0.45 EPS. Equities research analysts expect that Medtronic plc will post 4.2 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 22nd will be paid a dividend of $0.58 per share. The ex-dividend date of this dividend is Friday, December 18th. This represents a $2.32 annualized dividend and a dividend yield of 1.95%. Medtronic’s dividend payout ratio (DPR) is presently 50.54%.

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Read More: Neutral Rating

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.